Close inspection of the swimmers plot shows that 12 patients initially responding to CART-ddBCMA have relapsed, most by around 12 months, and in addition there was one death, though this was unrelated to disease or treatment.Īccordingly, at 18 months the response rate stands at 50% – 11 of 22 patients. However, many of the remissions are not proving durable. Current page 1 Next page next Last page last » Print Page. This is the same state of play as at the Asco data cutoff. Presentations Allogene June 2023 Corporate Presentation June 5, 2023. So far so good, and it must also be stressed that safety remains relatively clean: among grade 3 events there is just one cytokine release syndrome and two neurotoxicity cases. Christine arrives at a key inflection point for. And 27 of those 38 responses are complete. Christine Cassiano, SVP, Corporate Communications & Investor Relations, Kite Pharma (Photo: Business Wire). Half of Kite Pharma salaries are above 83,704. Average Kite Pharma salaries by department include: Operations at 83,606, HR at 89,320, IT at 94,607, and Admin at 46,027. All 31 patients previously detailed had gone into remission, and so have the extra seven patients now presented. At Kite Pharma, the highest paid job is a Sales Rep at 120,072 annually and the lowest is a Bookkeeper at 42,434 annually. This was on the basis of efficacy in line with Carvykti in an arguably harder-to-treat population, with possibly better safety to boot.Īt Ash it is adding seven patients to bring the evaluable dataset to 38 as of an October 31 cutoff. Shares of rivals Kite Pharma and Juno Therapeutics tanked Tuesday following presentations at the annual American Society of Hematology (ASH) conference, but Spark Therapeutics stock enjoyed its. The last time Arcellx presented CART-ddBCMA data, at Asco in June, it argued that the project, which is autologous but uses an artificial binding domain to hit BCMA, had “best-in-class potential”. The Gilead deal adds a key endorsement.īeing competitive in this space is especially hard given the huge number of BCMA-targeting projects in development, and the added availability as of October of J&J’s Tecvayli, a T-cell engaging MAb. J&J’s approved rival BCMA-directed Car-T therapy, Carvykti, has set a high bar which, once again, CART-ddBCMA seems to have met. We believe cell therapy has the ability to change the way cancer is treated. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Friday’s licensing deal saw the big biotech hand across $225m in cash and make a $100m equity investment for rights to the project.Īn investor update made available ahead of Arcellx’s Ash poster on Sunday sheds more light on the latest cut of the phase 1 CART-ddBCMA study that secured Gilead as a partner. Transformational Cancer Treatment At Kite, our singular focus is cell therapy to treat and potentially cure cancer. With Arcellx’s CART-ddBCMA maintaining its 100% track record of putting multiple myeloma patients into remission, according to data being presented at Ash, Gilead heard enough to sign on the dotted line.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |